Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of recombinant MAGE-3 protein with AS02B vs AS15 in metastatic cutaneous melanoma
2004-001937-40Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2006
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rMAGE-3 in melanoma (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Started Apr 2006; status: completed.
02
Drugs
rMAGE-3
03
Conditions
melanoma
Beyond the preview
Go deeper on 2004-001937-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001937-40.